Evidence map›Paper›PMID 37158965›Full record

ArticlePilot and feasibility studies2023

Development, implementation, and feasibility of site-specific hepatitis C virus treatment workflows for treating vulnerable, high-risk populations: protocol of the Erase Hep C study - a prospective single-arm intervention trial.

Anmol Desai, Lauren O'Neal, Kia Reinis, Patrick Chang, Cristal Brown, Michael Stefanowicz, Audrey Kuang, Deepak Agrawal, Darlene Bhavnani, Tim Mercer

Erratum issued Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pilot and feasibility studies, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05460130 (Implementation of a Simplified, Low-barrier Primary Care HCV Treatment Model for High Risk, High Prevalence Populations in Austin, Texas), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05460130 naunknown statusnot on this map

Implementation of a Simplified, Low-barrier Primary Care HCV Treatment Model for High Risk, High Prevalence Populations in Austin, Texas

TypeinterventionalSponsorUniversity of Texas at AustinRan2022 to 2023Enrolled64ConditionsHepatitis C Virus InfectionArmsSimplified Hepatitis C Virus (HCV) Treatment Protocol
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Anmol DesaiDepartment of Population Health, The University of Texas at Austin Dell Medical School, Austin, USA.
Lauren O'NealThe University of Texas at Austin Dell Medical School, Austin, USA.
Kia ReinisDepartment of Population Health, The University of Texas at Austin Dell Medical School, Austin, USA.
Patrick ChangDepartment of Population Health, The University of Texas at Austin Dell Medical School, Austin, USA.
Cristal BrownDepartment of Internal Medicine, The University of Texas at Austin Dell Medical School, Austin, USA.
Michael StefanowiczDepartment of Population Health, The University of Texas at Austin Dell Medical School, Austin, USA.
Audrey KuangDepartment of Population Health, The University of Texas at Austin Dell Medical School, Austin, USA.
Deepak AgrawalDepartment of Internal Medicine, The University of Texas at Austin Dell Medical School, Austin, USA.
Darlene BhavnaniDepartment of Population Health, The University of Texas at Austin Dell Medical School, Austin, USA.
Tim MercerDepartment of Population Health, The University of Texas at Austin Dell Medical School, Austin, USA. tim.mercer@austin.utexas.edu.ORCID http://orcid.org/0000-0002-8831-0569
The University of Texas at Austin · USMemorialCare Health System · USAustin Community College · US

Funding

Gilead Sciences IN-US-987-6016
6 · The paper itself

Abstract

backgroundHepatitis C virus (HCV) is the leading indication for liver transplantation and liver-related mortality. The development of direct-acting antivirals (DAA) and a simplified treatment algorithm with a > 97% cure rate should make global elimination of HCV an achievable goal. Yet, vulnerable populations with high rates of HCV still have limited access to treatment. By designing locally contextualized site-specific HCV treatment workflows, we aim to cure HCV in vulnerable, high-risk populations, including people experiencing homelessness (PEH) and people who inject drugs (PWID), in Austin, TX, USA.

methodsOur implementation science study will utilize a qualitative and design thinking approach to characterize patient and systemic barriers and facilitators to HCV treatment in vulnerable, high-risk populations seeking care across seven diverse primary care clinics serving PEHs and PWIDs. Qualitative interviews guided by the Practical, Robust Implementation and Sustainability Model (PRISM) framework will identify barriers and facilitators by leveraging knowledge and experience from both clinic staff and patients. Data synthesized using thematic analysis and design thinking will feed into workshops with clinic stakeholders for idea generation to design site-specific HCV treatment workflows. Providers will be trained on the use of a simplified HCV treatment algorithm with DAAs and clinic staff on the new site-specific HCV treatment workflows. These workflows will be implemented by the seven diverse primary care clinics serving vulnerable, high-risk populations. Implementation and clinical outcomes will be measured using data collected through interviews with staff as well as through medical chart review. DISCUSSION: Our study provides a model of how to contextualize and implement site-specific HCV treatment workflows targeting vulnerable, high-risk populations in other geographic locations. This model can be adopted for future implementation research programs aiming to develop and implement site-specific treatment workflows for vulnerable, high-risk populations and in primary care clinical settings for other disease states beyond just HCV.

trial registrationRegistered on ClinicalTrials.gov on July, 14, 2022. Identifier: NCT05460130 .

Indexed as

Direct-acting antiviralsHealthcare for the HomelessHepatitis C virusHomelessnessImplementation scienceIntravenous drug usePeople who inject drugsSimplified treatmentSite-specific treatmentSustained virological response

Identifiers

PMID37158965
PMCPMC10165844
OpenAlexW4375955282

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.